A biomarker has been identified that may help to identify patients with recurrent glioblastoma who stand to respond better to anti-VEGF endothelial growth factor therapy with cediranib. In a phase-2 ...

Several predictive biomarkers have been proposed for anti-VEGF therapies; however, no validated biomarkers for cancer treatment exist. For patients with glioblastoma, who have a dismal prognosis, ...

Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer No significant financial ...

TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the first subjects have been dosed in a Phase 1 study of AV-001 in healthy subjects.

TORONTO — Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, ...

Vascular functions of PlGF remain poorly understood and controversial. Here, we show that tumor cell-derived PIGF-1 and PIGF-2 displayed significant remodeling effects on the tumor vasculature, ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...